The start of the “sun-worshipping season” is a good time to review the basics of basal cell and squamous cell carcinomas.
Study results indicate that reactivation of the hepatitis C virus (HCV) in HIV-positive patients with lymphoma does not worsen survival outcomes.
CHICAGO, IL—Siltuximab, a novel chimeric anti−interleukin-6 monoclonal antibody, is active in patients with multicentric Castleman’s disease (MCD) who have had insufficient response to or failed previous therapies.
Janssen Biotech announced that the FDA has approved Sylvant (siltuximab) for the treatment of patients with multicentric Castleman’s disease (MCD) who are HIV negative and HHV-8 negative.
Nanopharmaceutical formulations might allow newly widespread adoption of old anticancer agents, with reduced toxic effects.
RiBVD regimen appears effective in elderly patients with untreated mantle cell lymphoma.
Siltuximab improves symptoms and clinical outcomes for patients with multicentric Castleman’s disease, despite a high rate of drug discontinuation due to toxicities, according to data presented at ASH 2013.
Performing early stem cell transplants in patients with aggressive non-Hodgkin lymphoma does not improve overall survival.
Standard and low-dose EPOCH-R treatment results in high rates of disease-free, overall survival in patients with Burkitt’s lymphoma.